Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Clark

Showing results (261-270 of 305) with videos related to

Pageof 31
Sort By:
Plos One|September 12, 2017
Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvementsAndrew Clark, Robert Black, Jacqueline Tate, et al.
Infectious Diseases and Therapy|September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Journal of Clinical Pharmacology|September 8, 2018
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected SubjectsManoli Vourvahis, Lynn McFadyen, Sunil Nepal, et al.
The Pediatric Infectious Disease Journal|October 13, 2017
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, et al.
The Lancet. Global Health|June 20, 2020
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling studyAndrew Clark, Mark Jit, Charlotte Warren-Gash, et al.
British Journal of Haematology|April 27, 2012
Organ-specific management and supportive care in chronic graft-versus-host diseaseFiona L Dignan, Julia J Scarisbrick, Jacqueline Cornish, et al.
Health Affairs (Project Hope)|February 6, 2018
The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing CountriesAngela Y Chang, Carlos Riumallo-Herl, Nicole A Perales, et al.
Antimicrobial Agents and Chemotherapy|May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Physical Chemistry Chemical Physics : PCCP|April 6, 2020
Time-resolved formation of excited atomic and molecular states in XUV-induced nanoplasmas in ammonia clustersRupert Michiels, Aaron C LaForge, Matthias Bohlen, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Pageof 31

Showing results (261-270 of 305) with videos related to

Sort By:
Pageof 31
Plos One|September 12, 2017
Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvementsAndrew Clark, Robert Black, Jacqueline Tate, et al.
Infectious Diseases and Therapy|September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Journal of Clinical Pharmacology|September 8, 2018
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected SubjectsManoli Vourvahis, Lynn McFadyen, Sunil Nepal, et al.
The Pediatric Infectious Disease Journal|October 13, 2017
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, et al.
The Lancet. Global Health|June 20, 2020
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling studyAndrew Clark, Mark Jit, Charlotte Warren-Gash, et al.
British Journal of Haematology|April 27, 2012
Organ-specific management and supportive care in chronic graft-versus-host diseaseFiona L Dignan, Julia J Scarisbrick, Jacqueline Cornish, et al.
Health Affairs (Project Hope)|February 6, 2018
The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing CountriesAngela Y Chang, Carlos Riumallo-Herl, Nicole A Perales, et al.
Antimicrobial Agents and Chemotherapy|May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Physical Chemistry Chemical Physics : PCCP|April 6, 2020
Time-resolved formation of excited atomic and molecular states in XUV-induced nanoplasmas in ammonia clustersRupert Michiels, Aaron C LaForge, Matthias Bohlen, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Pageof 31